Ian Frank, MD, discusses the future of HIV prevention and long-acting injectables.
Segment Description: Ian Frank, MD, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the future of HIV prevention and long-acting injectables.
Interview transcript (modified slightly for readability):
Contagion®: Are there any news therapies on the horizon for PrEP?
Ian Frank, MD: “The most exciting medication on the horizon for PrEP is cabotegravir which is a long-acting injectable medication.
There's a large study going on right now, being sponsored by the HIV Prevention Trial Network, that compares injectable cabotegravir versus oral tenofovir disoproxil fumarate and emtricitabine, the currently US Food and Drug Administration (FDA)-approved PrEP regimen. Cabotegravir is being evaluated as an every 2-month injection. If it's effective in that way it would alleviate the need to adhere to a daily regimen and could really transform the ease of PrEP administration and engagement so there's a lot of interest in that particular study.”
